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Introduction

Follicular lymphoma is a common germinal center (GC) B cell-derived non-Hodgkin lymphoma (NHL)
exhibiting a spectrum of morphologies, immunophenotypes, and genetic aberrations. It is the second most common type of NHL representing about 30% of NHL in western countries (1, 2) ; however, the incidence of FL is lower in Asian countries (3, 4) . A recent study of 98 Chinese FL cases revealed a lower frequency of BCL2 rearrangement in Chinese FL (58.5%) than in Western FL (80% to 90%) (5) . The BCL2 rearrangement results in constitutive expression of the antiapoptotic BCL2 protein, which plays an important role in tumorigenesis of FL; however, BCL2 rearrangement alone is not sufficient for malignant transformation of B cells. Multiple genetic abnormalities, including mutation of Enhancer of Zeste homolog 2 (EZH2), have recently been reported in FL (6) (7) (8) (9) . The EZH2 gene encodes a histone methyltransferase that constitutes the catalytic component of the polycomb repressive complex-2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).
EZH2 codon 641 mutation, the most common mutation hot-spot, is a gain-of-function mutation leading to enhanced trimethylation of histone H3K27 and plays an important role in the tumorigenesis of GCB-type DLBCL and FL (6) (7) (8) (9) (10) (11) . Interestingly, highly selective EZH2 inhibitors have now been developed which is a potential therapeutic strategy for lymphomas with EZH2 activating mutations (12) . However, it is unclear whether Chinese FL utilizes similar pathogenetic pathways as their Western counterpart and the frequency of EZH2 mutation in Chinese FL is not known. The aim of the present study is to identify the frequency of EZH2 gene codon 641 mutation in Chinese FL and the association with the status of BCL2 expression and rearrangement. We also analyzed the gene expression profiling (GEP) data of FLs with and without EZH2 gene mutation to identify unique associations with EZH2 mutation in FL. 
Materials and methods
Patient materials
124 Chinese FL diagnosed between January 1999 and May 2010 were obtained from Hong Kong and provinces of Shandong, Tianjing and Shaan Xi, China, among which 109 cases had BCL2 rearrangement data detected by interphase fluorescence in situ hybridization (FISH). We also included 70 Western FL with BCL2 rearrangement data detected by FISH from the University of Nebraska Medical Center for comparison. As FL without or without t(14;18) may evolve through different molecular pathways, our initial hypothesis is that EZH2 mutation may be present at different frequencies in FL with different t(14;18) status.
We enriched both cohorts with a substantial number of FL cases with no BCL2 rearrangement (From previous cytogenetics and FISH studies) to test the hypothesis as such cases are uncommon particularly in Western FL. The cases were reviewed by expert hematopathologists (J.K.C.C., W.C.C. and B.M.) and re-reviewed by W.C.C. and S.P.G, and classified based on the World Health Organization criteria. These cases showed at least 30%-40% of the sectional areas consisting of malignant follicles on hematoxylin and eosin (H&E) examination. This study was approved by the institution review boards of the respective institutions.
Construction of tissue microarray and immunohistochemistry
Representative areas of FL tissue blocks were selected to prepare the tissue microarray (TMA) by examination of the corresponding H&E stained slides. To ensure accurate representation, three areas of each tumor were selected for core preparation. Each target area on the selected blocks was punched to obtain a 1 mm diameter tissue core to be placed consecutively on the recipient master blocks. were added to form a final score to divide the cases from negative to strong TCL1A expression as described in supplementary Table 1A . Genomic DNA encompassing EZH2 codon 641 was PCR amplified using forward primer harboring an EZH2 codon Y641N mutation, and normal tonsil lacking EZH2 mutation, was mixed with SU-DHL-6 DNA constituting 5%, 10%, 20%, 30%, 50% and 70% of the total DNA respectively. The mixture was used as template to determine the sensitivity of pyrosequencing to detect the mutant. The sensitivity of the assay was determined to be at 5% of the genomic DNA of the cell line SU-DHL-6.
According to the principle of pyrosequencing, the light emission in the process of sequencing is proportional to the quantity of dNTPs incorporated into the template. dNTPs were dispensed in a novel order of G, A, A, T, C, G, A, T and C, based on the sequence of wild type EZH2 codon 641 and 5 mutation variants. With this order of addition, at least one addition results in nucleotide incorporation for the mutant but not the wild type allele, allowing all 5 mutations to be identified and detected with maximal sensitivity (Table 1 ). All detected mutations were validated by repeating the assay.
Gene expression profiling data analysis
The gene expression profiling (GEP) data from 68 cases of UNMC FL were analyzed to find genes differentially expressed between FLs with or without EZH2 mutation. We used HG-U133 plus 2 arrays (Affymetrix Inc.,Santa Clara, CA) for our analysis, and the methods for isolation and processing of RNA and acquisition of GEP raw data have been described previously (13) . The raw data were uploaded in BRB-Array Tools (version 3.7.0) for normalization, and the analysis was supervised by the EZH2 gene mutation status. Genes were selected at significance of p<0.01 and >1.5 fold difference in expression level between the two groups. To enhance the identification of differential gene expression in FL tumor cells, only FL cases with a high B-cell content (enriched B-cell signature of >2-fold above the mean of the B-cell signature (pan B-cell markers) in the entire FL data set) were chosen for analysis.
Statistical analysis
Research. Statistical significance of differences in EZH2 mutation frequency between lymphoma groups with or without BCL2 rearrangement and expression was assessed by chi-squared (χ 2 ) test. Statistical significance was defined as p<0.05.
Research. 
Results
Patient characteristics
124 Chinese FL patients were included in this study. The median age of these patients was 59.5 years (range, 26-89 years), and included 64 (51.6%) males and 60 (48.4%) females. These cases were enriched in BCL2 translocation negative cases so that only 56 harbored a BCL2 rearrangement and 68 lacked a BCL2 rearrangement. Among the 70 western FLs, the median age was 60 (range, 35-88 years) and there were 33 (47.1%) male and 37 (52.9%) female patients. This cohort was also enriched in BCL2 wild type cases, 39 harbored a BCL2 rearrangement and 31 lacked a BCL2 rearrangement. There were no significant differences in clinical features between Chinese and Western FLs. On histological morphological assessment, 72 of 124 (58%) in Chinese cohort and 39 of 70 cases (55.7%) in the Western cohort were of grade 1-2.
Frequencies of EZH2 codon 641 mutations
We observed EZH2 codon 641 mutations in 16.9% (21 of 124) Chinese FL and 18.6% (13 of 70) Western FLs using pyrosequencing and the results are summarized in Table 2 and histidine (H) as shown in Table1. These five variants were detected in Chinese FL with frequencies similar to those of Western FL. Y641F was the most common mutation, accounting for 38% of mutants, with decreasing frequencies from Y641S (24%), Y641H (14%), Y641C (14%) to Y641N (10%).
Differential gene expression analysis
Our analysis focused on FL cases with high B-cell contents to facilitate the detection of changes related to the tumor cells. A set of genes was significantly down-regulated in mutated cases. Among these down-regulated genes, a number of them, such as TCF4, FOXP1, TCL1A, BIK and RASSF6P were also marked repressed compared with normal centroblasts (Figure 3) . There was also a set of genes such as PTPN22, which was up-regulated in mutant cases probably as secondary changes. We also compared our signature with the specific gene signature derived previously using an EZH2-specific inhibitor (GSK126) on GCB cell lines with EZH2 mutation (12) .Notably, this signature was significantly (p<0.02) down-regulated in cases with EZH2 mutation compared with wild type cases ( Figure 3 ).
Down-regulation of TCL1A in EZH2 mutated FLs
One of the target genes that were reported to be up-regulated upon treatment of EZH2 mutant cell lines by a specific inhibitor of EZH2 mutant protein (GSK12) is TCL1A (ref 12). Consistent with this observation, we observed that this gene was down-regulated in FL cases carrying EZH2 Y641 mutation compared to our wild type. There have been reports suggesting variable expression of TCL1A in FL. We evaluated TCL1A expression at the protein level and observed that B cells in the mantle zone of reactive tonsil showed strong expression of TCL1A, whereas GC B-cells showed moderate expression in both cytoplasm and nucleus. Of the FL cases without EZH2 Y641 mutation, the majority of the FL cases (67.2%, 39 of 58) showed strong homogenous expression of TCL1A, whereas 10.3 % (6 of 58) were moderate, and 22.4% (13 of 58) were either weak or negative. Interestingly, none of the FL case with EZH2 Y641 mutation showed strong expression; it was generally variable from moderate (6 cases) to weak (1 case), or negative (3 cases) in 10 mutant cases. The results are summarized in supplementary Table 1B, 
Discussion
EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of lysine 27 of histone H3. The EZH2 codon 641 mutation is a gain-of-function mutation leading to enhanced trimethylation of histone H3K27 (6).
EZH2-mediated epigenetic silencing in GC-B cells contributes to proliferation and lymphomagenesis (14) .
The frequency of EZH2 mutations varied from 7.2% to 22% (Supplementary Table 2 ) in prior studies (7, (9) (10) ; the variation is probably due to the different methods used. Pyrosequencing was used in the present study because it is more sensitive than conventional Sanger sequencing and is widely used clinically to detect point mutations in FFPE tissues. The assay was able to detect 5% of the genomic DNA of the cell line SU-DHL-6, which harbors an EZH2 codon Y641N mutation. Assays with lower sensitivity may miss the mutation in cases with low tumor content, which are not uncommon in FLs. We detected a Y641F was the most common mutation, accounting for 38% of mutants. It has been reported that all of the five mutant proteins confer a gain-of-function phenotype and that Y641N is the most potent at generating H3K27me3, whereas Y641H is the least potent (8) .
The BCL2 rearrangement is a genetic hallmark of FLs, but a small percentage of FL cases lack this rearrangement; the latter are much more frequent in the Chinese population (5). It is possible that cases with or without BCL2 rearrangement may have different pathogenetic mechanisms that may be reflected in different profiles of genetic mutations. A recent study in Western patients indeed found a marked difference in EZH2 mutation frequency between the two subgroups (7). We investigated the association of EZH2 mutation and the status of BCL2 rearrangement in FL including a substantial number of cases with no BCL2 rearrangement. The frequency of EZH2 mutation was significantly associated with BCL2 rearrangement in Chinese FL, but did not reach statistical significance in western FL, probably due to the small number of cases. However overall (combining both cohorts) EZH2 mutation was significantly associated with BCL2 rearrangement. The frequency of EZH2 codon 641 mutation in Chinese FL with BCL2 rearrangement was very close to that reported in a previously study (28%), using a sensitive detection technique (7) . The mutation frequency in Chinese FL lacking BCL2 rearrangement was low and comparable to similar patients in Western countries but far higher than reported previously (7) . As EZH2 codon 641 mutation was first identified in a grade I FL lacking BCL2 rearrangement (9), the reported lack of EZH2 mutation in cases negative for BCL2 rearrangement (7) Although it has been demonstrated that the EZH2 codon 641 mutation enhances trimethylation of histone H3K27, the genomic targets that are affected by the mutation and thus promote lymphomagenesis have not been identified. Our GEP data analysis revealed a set of differentially expressed genes; among them TCF4, FOXP1, RASSF6, TCL1A and BIK were down-regulated, compared with both wild type FL and normal CB. Both TCF4 and FOXP1 were consistently up-regulated in ABC-DLBCL compared to GBC-DLBCL (15) . This observation suggests that one of the functions of EZH2 mutation may be locking the cells at the GCB cell stage of differentiation by down-regulating the expression of crucial genes for further differentiation. TCL1A is also of particularly interest; it was initially identified as an oncogene in T-cell prolymphocytic leukemias, but may also be expressed in B-cell lymphomas including FL (16) . TCL1A serves as a coactivator of the AKT/mTOR pathway and has also been reported as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL)
Research.
on April 21, 2017. © 2014 American Association for Cancer clincancerres.aacrjournals.org Downloaded from (17) , so down-regulation of TCL1A may have diverse effects including epigenetic alterations. We further confirmed the frequent expression of TCL1A protein in FLs. It was revealed that FLs displayed striking variability in the intensity of TCL1A staining and there is a correlation with EZH2 Y641 mutation. 39 cases showing strong positivity for TCL1A harbored no EZH2 Y641 mutation, whereas the expression of TCL1A in the mutant cases varied from moderate to weak, or negative, and none showed strong positivity. The IHC results are in keeping with the GEP analysis and may explain the reported variability of TCL1A expression in FL. Interestingly, it was also noted that the expression of TCL1A increased in DLBCL cell lines harboring EZH2 mutation when treated with the EZH2 specific inhibitor GSK126 (12) . This observation is consistent with our finding and suggests that TCL1A is likely gene targeted by EZH2 mutation in FL. We also observed that specific gene signature generated by EZH2 mutant inhibitor (GSK1206) (12) showed expected correlation in mutant FL cases, suggesting that such inhibitors may provide a rationale and viable therapeutic drug for these patients. Down-regulation of BIK (Bcl2-interacting killer), a pro-apoptotic gene, is also of interest as 40% of cases of multiple myeloma were reported to have a methylated BIK CpG island (18) . Another down-regulated gene is RASSF6, a Ras-association family (RASSF) member that has been shown to be frequently epigenetically inactivated by promoter CpG island hypermethylation in childhood leukemias (19) .
Among the up-regulated genes, PTPN22 is intriguing. The expression of PTPN22 in FLs with EZH2 mutation is significantly higher than in normal B-cells (naïve B cells, centrocytes, and centroblasts) and in FLs without EZH2 mutation. PTPN22 is considered to be one of the principal negative regulators of antigen-receptor signaling in normal B and T lymphocytes, but it can also positively regulate the kinase AKT, providing a powerful survival signal. B-cell receptor signaling in FL may need to be finely tuned to avoid further differentiation and simultaneous activating the AKT pathway may optimize cell survival, perhaps compensating for the effects of TCL1 down-regulation on the AKT/mTOR pathway (20) . EZH2 codon 641 mutation variants by adding dNTPs in the designated order (G,A,A,T,C,G,A,T,C Research. Mean   CCDC50  TCF4  SMAD1  CCL17  PTPN1  FAIM3  LOC221442  DOPEY2  MYO7A  TFPI2  CCL22  PLCL2  TRAM2  P2RY10  TCF4  TCF4  RRAS2  SC4MOL   Normal B -cell  subsets   CNKSR2  PVALB  ADD3  TFPI2  LOC374443  FZD3  MYO1D  TCF4  TCF4  FOXP1  TCF4  RASSF6  FOXP1  RASGRP2  IGHM  TCL1A   SC4MOL  CYP51A1  PTPN22  PTPN22  SPAG1  DHCR24  PTPN22  TXLNB  IRAK2  RANBP2  GRAMD1C  SYT11  BTNL9  ILDR1  TESK2  BRIP1 Pan B-cell signature (mean) TCL1A  TCL1A  BIK  E2F5  TAGAP   BRIP1  GATM  KCNH8  INPP5F  USP12  HS2ST1  TEX9  INPP5F  INPP5F  RRAS2  C2orf88  BFSP2 
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